Sacubitril/valsartan in chronic heart failure with reduced ejection fraction: a guide to its use

详细信息    查看全文

• 作者：Gillian M. Keating ; Paul L. McCormack
• 刊名：Drugs & Therapy Perspectives
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：33
• 期：1
• 页码：1-7
• 全文大小：
• 刊物主题：Pharmacy; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-1977
• 卷排序：33

文摘

Orally administered sacubitril/valsartan (Entresto®) comprises the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker valsartan, and was recently approved in the USA and the EU for the treatment of chronic heart failure (HF) with reduced ejection fraction (EF). In the PARADIGM-HF trial, the risk of death from cardiovascular causes or first hospitalization for worsening HF (primary composite endpoint) was significantly reduced with sacubitril/valsartan relative to the ACE inhibitor enalapril in patients with chronic HF with reduced EF. Sacubitril/valsartan was generally well tolerated, with a very low risk of angioedema. Therefore, as a first-in-class angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan represents a novel approach to the treatment of chronic HF with reduced EF.